Feb 16, 2019

23andMe wants to be a drug company

23andMe. Photo: Eric Baradat/AFP/Getty Images

23andMe is best known for its home DNA-testing kits, but it also wants to become a pharmaceutical company.

Driving the news: 23andMe is doing early research on 13 compounds, which could ultimately treat skin conditions, cancer and heart disease, Business Insider reports (subscription required).

  • The company has 70 scientists working on those compounds, plus 2 more potential drugs that are further along in the process.
  • And all of that comes on top of 23andMe's partnership with established drugmakers. It struck a $300 million deal with GlaxoSmithKline last year.

The intrigue: The overwhelming majority of efforts to create a new drug end in failure. But 23andMe is hoping its vast stores of human DNA information will give it a better shot, per Business Insider.

Go deeper

Pandemic forces startups to shift gears

Illustration: Eniola Odetunde/Axios

Spaces CEO Brad Herman had an early warning about COVID-19 because his startup supplies VR attractions to a number of theme parks in China. Realizing that the business he spent the last few years building was going to evaporate, Herman quickly found a new way to apply his team's know-how: helping companies host Zoom teleconferences in VR.

Why it matters: Many startups are rethinking the viability of their core businesses in the wake of the coronavirus. Spaces' move is one of many such pivots likely to crop up in the coming months.

International coronavirus treatment trial uses AI to speed results

Hydroxychloroquine is one of the drugs that will be included in the trial. Photo: John Philips/Getty Images

The first hospital network in the U.S. has joined an international clinical trial using artificial intelligence to help determine which treatments for patients with the novel coronavirus are most effective on an on-going basis.

Why it matters: In the midst of a pandemic, scientists face dueling needs: to find treatments quickly and to ensure they are safe and effective. By using this new type of adaptive platform, doctors hope to collect clinical data that will help more quickly determine what actually works.

Go deeperArrow46 mins ago - Health

We can't just flip the switch on the coronavirus

Illustration: Sarah Grillo/Axios

It feels like some big, terrible switch got flipped when the coronavirus upended our lives — so it’s natural to want to simply flip it back. But that is not how the return to normalcy will go.

The big picture: Even as the number of illnesses and deaths in the U.S. start to fall, and we start to think about leaving the house again, the way forward will likely be slow and uneven. This may feel like it all happened suddenly, but it won't end that way.